Applications of 6-Fluoro-1-Methyl-4-Oxo-7-(1-Piperazinyl)-4H-[1,3]Thiazeto[3,2-A]Quinoline-3-Carboxylic Acid in Industrial Manufacturing

Our plant-scale expertise in synthesizing 6-Fluoro-1-Methyl-4-Oxo-7-(1-Piperazinyl)-4H-[1,3]Thiazeto[3,2-A]Quinoline-3-Carboxylic Acid supports key downstream industries through direct supply of this high-purity quinoline derivative, addressing specific molecular requirements for advanced pharmaceutical intermediates. Below, we detail major industrial manufacturing applications observed in global downstream sectors, focusing on formulation integration, sector regulations, usage norms, and final dosage forms.

1. Fluoroquinolone Antibiotic APIs Production

As a core building block for new-generation fluoroquinolone antibiotics, multinational API manufacturers integrate this intermediate into late-stage synthetic routes for compounds such as thiazeto-based fluoroquinolones. Direct input at the penultimate synthesis step ensures strict impurity profile control demanded by international regulatory filings. Bulk supply consistency and analytical documentation facilitate its adoption in multi-ton campaigns at cGMP pharmaceutical facilities across Asia, Europe, and North America.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
• European Pharmacopoeia Monographs (Ph. Eur.) for Quinolone Derivatives
• U.S. FDA 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals
• WHO Guidelines for APIs and Pharmaceuticals

Typical usage ratio

• Dosage typically 1:1 stoichiometry (w/w) with corresponding aminopiperazine reactant in step-growth synthesis; yield-based adjustment per process validation (average 0.8–1.2 molar equivalents)

Downstream process integration

• Feeds directly into heterocyclic coupling and ring-closure reactor, often as a pre-purified solid or solution-in-process batch scale

Final product types

• Active pharmaceutical ingredients (APIs) for hospital and veterinary anti-infective drugs
• Bulk generic fluoroquinolone antibiotic APIs for tablet, injectable, and ophthalmic dosage forms

2. Custom Synthesis of Thiazetoquinoline-Based Research Compounds

Leading contract research organizations and in-house pharmaceutical R&D teams select our raw material for rapid exploration and optimization of novel antibacterial entities. Delivered under controlled documentation and traceable supply chains, the compound enables medicinal chemists to generate diverse analogs in mg through kg quantities as part of structure-activity relationship (SAR) workflows. Its consistent physical characteristics minimize batch-to-batch variables in route scouting runs.

Industry compliance standards

• Good Laboratory Practice (GLP, OECD Principles)
• ISO 9001:2015 Quality Management Systems
• REACH Regulation EC 1907/2006 (for EU-bound R&D use)
• NIH Guidelines for Chemical Research Materials

Typical usage ratio

• Typically charged at 0.5–2.5 mmol per laboratory-scale batch; actual quantities vary depending on desired analog library scale and parallel synthesis strategies

Downstream process integration

• Prepared as starting material in intermediate coupling or derivatization, followed by solution-phase modifications, and purified via flash chromatography or preparative HPLC

Final product types

• Discovery-phase thiazetoquinoline analog libraries
• Lead candidate compounds for preclinical in vitro/vivo studies

3. Industrial-Scale Process R&D for Manufacturing Route Optimization

Process development centers of major pharmaceutical manufacturers employ this compound to optimize scalable, reproducible routes for registered fluoroquinolone drugs. Focused on cost and yield efficiency, downstream teams test alternate process steps—such as green solvent exchange, improved crystallization, and impurity reduction—using our raw material in pilot-plant volumes with real-time analytical QC. Data derived from these experiments inform global regulatory submissions for full-scale commercial supply.

Industry compliance standards

• ICH Q11: Development and Manufacture of Drug Substances
• U.S. FDA Guidance on Process Validation: General Principles and Practices
• PIC/S GMP Guide PE009-15
• EMEA QP Certification Requirements

Typical usage ratio

• Batch inputs adjusted per pilot scale: typically 250–1,000 grams per test, scaled up in kilo-scale optimization batches; ratio set by target process yield and impurity mass balance studies

Downstream process integration

• Used at defined control points for crystallization, purification, or route-step alteration in 50–500 L reactors; in-line monitoring ensures quality data for process selection

Final product types

• Pilot-scale registration batches for regulatory filing
• Validated process intermediates for commercial API production

4. Precursor Supply for Analytical Reference Material Production

Accredited analytical standards manufacturers utilize our compound to construct Certified Reference Materials (CRMs) tailored for pharmaceutical laboratories calibrating HPLC, GC-MS, and NMR systems in quality control and release testing. Supplying ultra-high-purity raw material minimizes baseline impurities, allowing for accurate metrological traceability and external proficiency testing submissions under global accreditation schemes.

Industry compliance standards

• ISO/IEC 17025 Testing and Calibration Laboratories Accreditation
• ISO 17034 General Requirements for the Competence of Reference Material Producers
• USP Reference Standard Requirements
• European Pharmacopoeia General Notices for Analytical Standards

Typical usage ratio

• Conversion factor: 10–50 mg per preparation in CRM synthesis, adjusted for target purity and analytical batch volume; repeated verification across lots

Downstream process integration

• Subdivided in controlled-environment weighing, dissolved and purified to 99.9%+ by repeated recrystallization, then certified by complete spectral analysis and comparison to international standards

Final product types

• Analytical reference standards in ampoule or vial form for QC laboratories
• Metrological traceable fluoroquinolone benchmarks for regulatory submissions

5. Specialty Input for Veterinary Antibacterial Formulation Development

Veterinary pharmaceutical manufacturers integrate this chemical intermediate as a designated precursor for the synthesis of next-generation fluoroquinolone APIs designed for livestock and companion animal disease management. Compliance with veterinary health regulations and detailed impurity reporting ensures tested suitability through proprietary formulation pipelines, supporting finished product batches destined for regional approval and commercial distribution under veterinary medicinal product guidelines.

Industry compliance standards

• VICH GL3: Good Manufacturing Practice for APIs (Veterinary Use)
• European Pharmacopoeia (Ph. Eur.) Veterinary Supplement
• China Veterinary Drug GMP (2020 Edition)
• U.S. FDA Center for Veterinary Medicine (CVM) Guidelines

Typical usage ratio

• Calculated in the range of 0.9–1.1 molar equivalents per targeted veterinary API synthesis, adjusted based on animal species-specific dosage requirements and pharmacokinetic properties

Downstream process integration

• Fed as purified input to final API condensation or ring formation steps; subjected to species-specific impurity and residual solvent analysis prior to downstream formulation

Final product types

• Raw APIs for oral suspensions, injectables, and feed additives for animal health
• Formulated veterinary fluoroquinolone drugs for market authorization submission